24
Participants
Start Date
October 18, 2023
Primary Completion Date
October 1, 2025
Study Completion Date
October 1, 2025
CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16
Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10\^6 CD4+ cells/kg; 2) 5 x 10\^6 CD4+ cells/kg; or 3) 10\^7 CD4+ cells/kg of recipient ideal body weight.
Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16
Standard dosing for bone marrow graft (target dose of 4 x 10\^8 nucleated cells/kg) and if progression at Day 90, will receive dose level 1 for the CD8-depleted DLI (106 CD4+ cell/kg).
RECRUITING
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
PapiVax Biotech, Inc.
OTHER
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER